RGNXREGENXBIO Inc.
Price
-45%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growth steady, the market against it.
Charts
As reported to the SEC, without any scoring.
REGENXBIO Inc. (RGNX) reported revenue of $108M in Q2 2026 (quarter ended Jun 30, 2026), up 406% from the same quarter a year earlier. That came with net income of $23M (21% of revenue). For the full year FY2025, revenue was $170M (+105% year on year) and net income −$194M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 16, 2026On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the “Board”) of REGENXBIO Inc. (the “Company”) effective October 21, 2026.Director or officer change · Form 8-K
- Sep 23, 2026On September 23, 2026, REGENXBIO Inc. (the “Company”) and The Trustees of the University of Pennsylvania (“UPenn”) entered into a Settlement Agreement (the “Settlement Agreement”) with Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC (together with Sarepta Therapeutics, Inc., “Sarepta”) and Catalent …Material agreement entered · Form 8-K
- Aug 25, 2026On August 25, 2026, the Board of Directors (the “Board”) of REGENXBIO Inc. (the “Company”), elected Gregory Ciongoli as a Class II director of the Company effective immediately.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.